Please use this identifier to cite or link to this item:
Title: Revised recommendations for the management of Gaucher disease in children
Authors: Kaplan, Paige
Baris, Hagit
De Meirleir, Linda
Di Rocco, Maja
El-Beshlawy, Amal
Huemer, Martina
Martins, Ana Maria [UNIFESP]
Nascu, Ioana
Rohrbach, Marianne
Steinbach, Lynne
Cohen, Ian J.
Univ Penn
Tel Aviv Univ
UZ Brussels
Gaslini Inst
Cairo Univ
LKH Bregenz
Universidade Federal de São Paulo (UNIFESP)
Childrens Hosp Emergency Cluj
Univ Childrens Hosp
Univ Calif San Francisco
Keywords: Gaucher disease type 1
Gaucher disease type 2
Gaucher disease type 3
Enzyme replacement therapy
Genetic counseling
Disease management
Treatment recommendations
Issue Date: 1-Apr-2013
Publisher: Springer
Citation: European Journal of Pediatrics. New York: Springer, v. 172, n. 4, p. 447-458, 2013.
Abstract: Gaucher disease is an inherited pan-ethnic disorder that commonly begins in childhood and is caused by deficient activity of the lysosomal enzyme glucocerebrosidase. Two major phenotypes are recognized: non-neuropathic (type 1) and neuropathic (types 2 and 3). Symptomatic children are severely affected and manifest growth retardation, delayed puberty, early-onset osteopenia, significant splenomegaly, hepatomegaly, thrombocytopenia, anemia, severe bone pain, acute bone crises, and fractures. Symptomatic children with types 1 or 3 should receive enzyme replacement therapy, which will prevent debilitating and often irreversible disease progression and allow those with non-neuropathic disease to lead normal healthy lives. Children should be monitored every 6 months (physical exam including growth, spleen and liver volume, neurologic exam, hematologic indices) and have one to two yearly skeletal assessments (bone density and imaging, preferably with magnetic resonance, of lumbar vertebrae and lower limbs), with specialized cardiovascular monitoring for some type 3 patients. Response to treatment will determine the frequency of monitoring and optimal dose of enzyme replacement. Treatment of children with type 2 (most severe) neuropathic Gaucher disease is supportive. Pre-symptomatic children, usually with type 1 Gaucher, increasingly are being detected because of affected siblings and screening in high-prevalence communities. in this group, annual examinations (including bone density) are recommended. However, monitoring of asymptomatic children with affected siblings should be guided by the age and severity of manifestations in the first affected sibling. Treatment is necessary only if signs and symptoms develop. Conclusion: Early detection and treatment of symptomatic types 1 and 3 Gaucher disease with regular monitoring will optimize outcome. Pre-symptomatic children require regular monitoring. Genetic counseling is important.
ISSN: 0340-6199
Other Identifiers:
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.